SYTE.bio is a Synthetic Biology Start-Up company developing precision DNA & RNA-based therapeutics and vaccines. The company has been incorporated as a Delaware C Corp in 2021 (SYTE.bio, Inc), and has labs & offices in Argentina's headquarter, that has been operating since 2017. SYTE.bio is pioneering the development of life-changing treatments for severe diseases and vaccines to treat and prevent diseases at the molecular and cellular level using engineered DNA, improving life through innovation.
SYTE.bio’s powerful redosable DNA & RNA delivery platforms will unleash the potential of personalized genetic medicine in multiple potential applications, such as Gene Therapy (Oncology, Monogenic Diseases, Cardiovascular Diseases, Vaccines, Orphan Diseases), Cell Therapy (CAR-T Therapy, Induced Pluripotent Stem Cells (iPSC)) and Gene Editing (CRISPR/Cas, TALEN, ZFN).
Company Details
- Employees
- 11
- Address
- Boston, Massachusetts, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.syte.bio
- Keywords
- Evanston.
- HQ
- Boston, Massachusetts
Syte.bio Questions
Syte.Bio's website is http://www.syte.bio
Syte.Bio's LinkedIn profile is https://www.linkedin.com/company/sytebio
Syte.Bio has
11 employees.
View email and phone details for 11
employees at Syte.Bio.
Syte.Bio's industry is
Biotechnology Research
Syte.Bio's top competitors are
Athergen, Inc.,
Zs,
Remix Therapeutics,
Biosidus,
Asociación Argentina De Biología Sintética,
Puna Bio,
Limay Biosciences,
Spherebio,
Biomakers,
Bio Strategy Advisors.
Syte.Bio's categories are Biotechnology Research
